Tsuneo Saga

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1341976/publications.pdf

Version: 2024-02-01

315739 394421 1,474 49 19 38 citations h-index g-index papers 51 51 51 1431 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo. Annals of Nuclear Medicine, 2022, 36, 319.	2.2	1
2	Detection efficacy of PET/CT with 18F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. Annals of Nuclear Medicine, 2022, 36, 302.	2.2	1
3	Qualitative and Quantitative Assessment of Nonlocal Means Reconstruction Algorithm in a Flexible PET Scanner. American Journal of Roentgenology, 2021, 216, 486-493.	2.2	3
4	Increased [18F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors. EJNMMI Research, 2021, 11, 9.	2.5	4
5	Clinical value of PET/CT with carbon-11 4DST in the evaluation of malignant and benign lung tumors. Annals of Nuclear Medicine, 2021, 35, 211-222.	2.2	1
6	First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [18F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas. Frontiers in Endocrinology, 2021, 12, 717101.	3. 5	12
7	Physiologically decreased F-18 fluorodeoxyglucose uptake in the lower vertebrae associated with daily drinking habit in Japanese men with alcohol flushing reaction. Alcohol, 2021, 95, 15-23.	1.7	1
8	Deep Learning-based Noise Reduction for Fast Volume Diffusion Tensor Imaging: Assessing the Noise Reduction Effect and Reliability of Diffusion Metrics. Magnetic Resonance in Medical Sciences, 2021, 20, 450-456.	2.0	11
9	Imaging of Hypoxic Tumor: Correlation between Diffusion-weighted MR Imaging and ¹⁸ F-fluoroazomycin Arabinoside Positron Emission Tomography in Head and Neck Carcinoma. Magnetic Resonance in Medical Sciences, 2020, 19, 276-281.	2.0	6
10	Performance Evaluation of a Newly Developed MR-Compatible Mobile PET Scanner with Two Detector Layouts. Molecular Imaging and Biology, 2020, 22, 407-415.	2.6	4
11	Predominance and homogeneity patterns of physiological FDG accumulation in thoracic and lumbar vertebrae: suspected mechanism of "bone pseudometastasis―on FDG-PET in Japanese patients with esophageal cancer. Annals of Nuclear Medicine, 2020, 34, 182-191.	2.2	1
12	Prognostic utility of FDG PET/CT in advanced ovarian, fallopian and primary peritoneal high-grade serous cancer patients before and after neoadjuvant chemotherapy. Annals of Nuclear Medicine, 2020, 34, 128-135.	2.2	10
13	Prognostic Value of Quantitative Parameters of ¹⁸ F-FDG PET/CT for Patients With Angiosarcoma. American Journal of Roentgenology, 2020, 214, 649-657.	2.2	16
14	Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression. International Journal of Molecular Sciences, 2020, 21, 2304.	4.1	5
15	Increased 14C-acetate accumulation in IDH-mutated human glioblastoma: implications for detecting IDH-mutated glioblastoma with 11C-acetate PET imaging. Journal of Neuro-Oncology, 2019, 145, 441-447.	2.9	8
16	Therapeutic efficacy evaluation of radioimmunotherapy with 90 Yâ€labeled antiâ€podoplanin antibody NZ â€12 for mesothelioma. Cancer Science, 2019, 110, 1653-1664.	3.9	13
17	Initial evaluation of PET / CT with 18 F―FSU â€880 targeting prostateâ€specific membrane antigen in prostate cancer patients. Cancer Science, 2019, 110, 742-750.	3.9	10
18	CAST Diagnostic Imaging. , 2019, , 289-307.		0

#	Article	IF	Citations
19	Enhanced intestinal 2-deoxy-2-[¹⁸ F]fluoro-D-glucose uptake under metformin is not fully suppressed by loperamide. Endocrine Regulations, 2018, 52, 185-191.	1.3	2
20	Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with 90Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody 059-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer. International Journal of Molecular Sciences, 2018, 19, 2979.	4.1	18
21	Do TSH, FT3, and FT4 Impact BAT Visualization of Clinical FDG-PET/CT Images?. Contrast Media and Molecular Imaging, 2018, 2018, 1-9.	0.8	2
22	Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging. Bioengineering, 2017, 4, 78.	3.5	23
23	Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti- $\hat{l}\pm6\hat{l}^24$ integrin antibody. Oncotarget, 2016, 7, 38835-38844.	1.8	15
24	Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models. PLoS ONE, 2015, 10, e0123761.	2.5	30
25	Discovery of an uncovered region in fibrin clots and its clinical significance. Scientific Reports, 2013, 3, 2604.	3.3	44
26	Evaluation of 89Zr-Labeled Human Anti-CD147 Monoclonal Antibody as a Positron Emission Tomography Probe in a Mouse Model of Pancreatic Cancer. PLoS ONE, 2013, 8, e61230.	2.5	34
27	Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer. PLoS ONE, 2013, 8, e59248.	2.5	27
28	ZDHHC8 knockdown enhances radiosensitivity and suppresses tumor growth in a mesothelioma mouse model. Cancer Science, 2012, 103, 203-209.	3.9	26
29	PET/CT with $3\hat{a}\in^2$ -deoxy- $3\hat{a}\in^2$ -[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy. Nuclear Medicine Communications, 2011, 32, 348-355.	1.1	18
30	Clinical value of FDG-PET for preoperative evaluation of endometrial cancer. Annals of Nuclear Medicine, 2011, 25, 269-275.	2.2	18
31	C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model. Nuclear Medicine and Biology, 2010, 37, 179-187.	0.6	25
32	Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiotherapy and Oncology, 2010, 97, 200-204.	0.6	71
33	Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nuclear Medicine and Biology, 2009, 36, 379-388.	0.6	21
34	Evaluation of Primary Brain Tumors With FLT-PET: Usefulness and Limitations. Clinical Nuclear Medicine, 2006, 31, 774-780.	1.3	86
35	18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Annals of Nuclear Medicine, 2004, 18, 669-674.	2.2	60
36	Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Annals of Nuclear Medicine, 2003, 17, 197-203.	2.2	109

#	Article	IF	CITATIONS
37	Microâ€MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimerâ€based MR contrast agents. Journal of Magnetic Resonance Imaging, 2001, 14, 705-713.	3.4	86
38	Novel intravascular macromolecular MRI contrast agent with generation-4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine. Magnetic Resonance in Medicine, 2001, 46, 457-464.	3.0	41
39	3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent. Magnetic Resonance in Medicine, 2001, 46, 579-585.	3.0	45
40	Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magnetic Resonance in Medicine, 2001, 46, 1169-1173.	3.0	127
41	3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magnetic Resonance in Medicine, 2001, 45, 454-460.	3.0	143
42	Clinical Value of Positron Emission Tomography with FDG for Recurrent Ovarian Cancer. American Journal of Roentgenology, 2001, 176, 1449-1454.	2.2	144
43	Avidin Chase Can Reduce Myelotoxicity Associated with Radioimmunotherapy of Experimental Liver Micrometastases in Mice. Japanese Journal of Cancer Research, 2000, 91, 622-628.	1.7	4
44	FDG-PET of autoimmune-related pancreatitis: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1835-1838.	2.1	97
45	Radioimmunotherapy for Liver Micrometastases in Mice: Pharmacokinetics, Dose Estimation, and Long-term Effect. Japanese Journal of Cancer Research, 1999, 90, 342-348.	1.7	10
46	Imaging of intraperitoneal tumors with technetium-99m GSA. Annals of Nuclear Medicine, 1998, 12, 115-118.	2.2	20
47	Effect of Circulating Antigen on Immunoscintigraphy of Ovarian Cancer Patients Using Anti-CA125 Monoclonal Antibody. Japanese Journal of Cancer Research, 1996, 87, 655-661.	1.7	5
48	Immunohistochemical Localization of CA130 in Fetal Tissues, and in Normal and Neoplastic Tissues of the Female Genital Tract. Asia-Oceania Journal of Obstetrics and Gynaecology, 1990, 16, 379-387.	0.0	7
49	Immunoscintigraphy and Pharmacokinetics of Indium-111-labeled ZME-018 Monoclonal Antibody in Patients with Malignant Melanoma. Japanese Journal of Cancer Research, 1988, 79, 973-981.	1.7	9